A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers
Primary Purpose
Foot Ulcer, Diabetic
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Wound Dressing
Wound Dressing
Sponsored by
About this trial
This is an interventional treatment trial for Foot Ulcer, Diabetic focused on measuring Diabetic, Foot, Ulcer, Neuropathic, Tegaderm Matrix Dressing, DFU, Wound Care, PHI
Eligibility Criteria
Inclusion Criteria:
- Is the subject 18 years of age or older?
- Does the subject have a chronic full thickness diabetic foot ulcer (DFU) inferior to the malleolus that has been present for a minimum of four (4) weeks?
- Does the diabetic foot ulcer measure greater than 1.0 cm2 and less than 25.0 cm2 after the wound is debrided?
- Does the subject show evidence of neuropathy?
- Is the subject's wound free of tunneling and showing no exposed periosteum or bone and free of clinical infection defined as the presence of local signs and symptoms including purulence, warmth, tenderness, pain, induration, cellulitis, bullae, crepitus, abscess, fasciitis and osteomyelitis?
- Is the study wound able to be off loaded or achieve pressure relief and permit daily dressing changes?
- Is the subject willing to have three (3) wound biopsies taken (Visit 0, 4 and 8)?
- Is the subject willing to have photos taken of their wound and permit use of the photos in publications?
- Has the subject or their legally authorized representative signed an Institutional Review Board approved informed consent document and authorized the use and disclosure of protected health information?
- Does the subject have adequate circulation to the foot as evidenced by an Ankle Brachial Index (ABI) of 0.8 - 1.2; or if the ABI is greater than 1.2, does the subject show toe pressures >40 mmHg, or transcutaneous oximetry (TcPO2) > 40 mm Hg, or does the subject show adequate circulation on an arterial Doppler study? (ABI or Doppler results must be < 45 days old.)
- Is the subject able to comply with the protocol requirements?
- If the subject is a woman of child bearing potential is she practicing an acceptable form of birth control as determined by the Investigator, and is she willing to have a pregnancy test?
Exclusion Criteria:
- Is the subject pregnant or breast feeding or have they given birth within the 3 weeks preceding the screening visit?
- Has the subject been diagnosed with a malignant disease and received chemotherapy or treatment for a malignancy within the past 1 year?
- Does the subject have an infection requiring systemic antibiotic treatment?
- Has the subject ever received radiation therapy or other local therapy for malignancy at the extremity where the wound is located (from patient history)?
- Is the subject currently using systemic steroids, or have they used systemic steroids within the previous 2 weeks, or are they projected to require systemic steroid use during the study as evidenced by a history of chronic systemic steroid use? (Topical steroids (except on the study extremity) and steroid inhalants will be allowed in the study.)
- Does the subject have Lupus or Crohn's disease?
- Does the subject have an oxygen dependency?
- Has the subject received hyperbaric oxygen therapy within the previous 90 days?
- Has the subject had vascular surgery relating to the wound within 30 days prior to the Screening Visit?
- Does the subject have an active Charcot foot deformity of the foot presenting the ulcer?
- Has the subject received Dermagraft®, Apligraf, or any other biologically active wound care product, or used Regranex Gel®, KGF, TGFβ or another topical growth factor to the study ulcer within the 30 days prior to the Screening visit?
- Does the subject's wound require the use of topical silver, topical antibiotics, enzymatic debridement agents or other topical agents?
- Has the subject been enrolled in any investigational study within 30 days of the Screening Visit?
- Does the subject have any medical condition that in the opinion of the investigator should exclude him/her from participating in the study?
- Has the subject received ultrasonic debridement or electrical stimulation within 7 days of the Screening Visit?
Sites / Locations
- Terry Treadwell, MD
- Alex Reyzelman, DPM
- Wyatt Payne, MD
- Vickie Driver, DPM
- William Marston, MD
- Joseph Boykin, MD
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Non-adherent Wound Dressing
Tegaderm Matrix Dressing with PHI
Arm Description
The non-adherent dressing is the same as the Tegaderm Matrix dressing, with potassium chloride, rubidium chloride, calcium chloride, zinc chloride, potassium citrate and citric acid removed. This dressing is a Class I medical device (21 CFR Sec. 878.4020 Occlusive wound dressing) that is exempt from premarket notification procedures.
A commercial wound dressing to be used per manufacturer's instructions for use.
Outcomes
Primary Outcome Measures
Percent Diabetic Foot Ulcer Area Reduction From Baseline to Last Treatment Visit
A positive value indicates a reduction in area relative to baseline, while a negative value indicates an increase in area relative to baseline (at time of randomization), calculated as [(Baseline - Week 8)/Baseline] x 100%.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01013792
Brief Title
A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers
Official Title
A Multi-centered, Prospective, Randomized, Double-blinded, Comparison of an Investigational Non-adherent Dressing to 3M Tegaderm Matrix Dressing With PHI Technology in the Management of Non-healing Diabetic Foot Ulcers
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Terminated
Why Stopped
Expired study materials; low subject recruitment
Study Start Date
November 2009 (undefined)
Primary Completion Date
July 2012 (Actual)
Study Completion Date
July 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
3M
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective is to:
Assess the effect of the Non-adherent study dressing to 3M Tegaderm Matrix Dressing with PHI technology on wound healing in patients with a diabetic foot ulcer.
Secondary objectives are to:
Assess the adverse events that occur in subjects randomized to the investigational dressing in comparison to subjects randomized to the Tegaderm Matrix Dressing with PHI technology.
Assess the costs of using the investigational dressing compared to the Tegaderm Matrix Dressing with PHI technology.
Assess and compare the impact that these dressings have on patients' quality of life.
Assess the wound's biological response and pH to the study dressings.
Detailed Description
The primary objective of this study is to compare the effect of an investigational, non-adherent dressing to a commercial wound dressing, 3M™ Tegaderm™ Matrix Dressing with PHI™ technology (Matrix dressing), in the management of diabetic foot ulcers. Subjects' wounds will be observed for a four week, pre-treatment period with wound assessments being made and samples of wound fluid and tissue collected and analyzed to characterize the wound. Following this pre-treatment observational stage, subjects continuing to meet inclusion/exclusion criteria will be randomly assigned, with stratification by center, wound size and wound duration, in either of two groups in the eight week treatment stage of the study. Subjects in one group will have their wound managed with an investigational non-adherent dressing, and subjects in the other group will have their wound managed with a Matrix dressing. At Visit 4 (start of the treatment stage of the study), subjects with a study wound that is less than 1 cm2 at this point will be dropped from the study. A second investigational device will be used to measure the pH of the wound, which will be compared to wound healing data.
Pre-treatment Stage Secondary Objectives
To measure and compare changes in wound size and wound assessments with changes in wound biomarker levels, wound pH, microbial load, and changes in systemic levels of C-reactive protein and homocysteine.
To measure and compare changes in wound biomarker levels, pH, and microbial load, and changes in systemic (blood) levels of C-reactive protein and homocysteine, looking for relationships.
Treatment Stage Secondary Objectives
To measure and compare the incidence of adverse events experienced by subjects in each of the 2 treatment groups.
To measure and compare the wound characteristics of each treatment group.
To measure and compare the subjects' quality of life of each treatment group.
To measure and compare the cost effectiveness of each treatment group.
To measure and compare changes in wound size with changes in wound biomarker levels, pH, and microbial load; and changes in systemic (blood) levels of C-reactive protein and homocysteine.
To measure and compare changes in wound biomarker levels, pH, microbial load, and changes in systemic levels of C-reactive protein and homocysteine, looking for relationships within treatment groups and overall.
To assess the ease of using these dressing
Post-treatment Stage Secondary Objectives
Subjects whose wounds heal prior to Visit 12 are expected to have a follow-up appointment 12-14 weeks after their wound has healed. Subjects whose wounds do not heal by Visit 12 are expected to complete a follow-up appointment 12-14 weeks after their last appointment. The objectives of this are to determine the frequency of complete healing between the two treatment groups and to determine the number of wounds that had healed by the end of the treatment phase and remained healed for each group at the follow-up appointment.
The objective is to measure and compare the percentage of wounds healed by Visit 12 (or before) that remained healed at the follow-up appointment by treatment group.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Foot Ulcer, Diabetic
Keywords
Diabetic, Foot, Ulcer, Neuropathic, Tegaderm Matrix Dressing, DFU, Wound Care, PHI
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Non-adherent Wound Dressing
Arm Type
Experimental
Arm Description
The non-adherent dressing is the same as the Tegaderm Matrix dressing, with potassium chloride, rubidium chloride, calcium chloride, zinc chloride, potassium citrate and citric acid removed. This dressing is a Class I medical device (21 CFR Sec. 878.4020 Occlusive wound dressing) that is exempt from premarket notification procedures.
Arm Title
Tegaderm Matrix Dressing with PHI
Arm Type
Active Comparator
Arm Description
A commercial wound dressing to be used per manufacturer's instructions for use.
Intervention Type
Device
Intervention Name(s)
Wound Dressing
Intervention Description
Acetate mesh carrier with ointment (water, PEGs)
Intervention Type
Device
Intervention Name(s)
Wound Dressing
Intervention Description
Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)
Primary Outcome Measure Information:
Title
Percent Diabetic Foot Ulcer Area Reduction From Baseline to Last Treatment Visit
Description
A positive value indicates a reduction in area relative to baseline, while a negative value indicates an increase in area relative to baseline (at time of randomization), calculated as [(Baseline - Week 8)/Baseline] x 100%.
Time Frame
up to 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Is the subject 18 years of age or older?
Does the subject have a chronic full thickness diabetic foot ulcer (DFU) inferior to the malleolus that has been present for a minimum of four (4) weeks?
Does the diabetic foot ulcer measure greater than 1.0 cm2 and less than 25.0 cm2 after the wound is debrided?
Does the subject show evidence of neuropathy?
Is the subject's wound free of tunneling and showing no exposed periosteum or bone and free of clinical infection defined as the presence of local signs and symptoms including purulence, warmth, tenderness, pain, induration, cellulitis, bullae, crepitus, abscess, fasciitis and osteomyelitis?
Is the study wound able to be off loaded or achieve pressure relief and permit daily dressing changes?
Is the subject willing to have three (3) wound biopsies taken (Visit 0, 4 and 8)?
Is the subject willing to have photos taken of their wound and permit use of the photos in publications?
Has the subject or their legally authorized representative signed an Institutional Review Board approved informed consent document and authorized the use and disclosure of protected health information?
Does the subject have adequate circulation to the foot as evidenced by an Ankle Brachial Index (ABI) of 0.8 - 1.2; or if the ABI is greater than 1.2, does the subject show toe pressures >40 mmHg, or transcutaneous oximetry (TcPO2) > 40 mm Hg, or does the subject show adequate circulation on an arterial Doppler study? (ABI or Doppler results must be < 45 days old.)
Is the subject able to comply with the protocol requirements?
If the subject is a woman of child bearing potential is she practicing an acceptable form of birth control as determined by the Investigator, and is she willing to have a pregnancy test?
Exclusion Criteria:
Is the subject pregnant or breast feeding or have they given birth within the 3 weeks preceding the screening visit?
Has the subject been diagnosed with a malignant disease and received chemotherapy or treatment for a malignancy within the past 1 year?
Does the subject have an infection requiring systemic antibiotic treatment?
Has the subject ever received radiation therapy or other local therapy for malignancy at the extremity where the wound is located (from patient history)?
Is the subject currently using systemic steroids, or have they used systemic steroids within the previous 2 weeks, or are they projected to require systemic steroid use during the study as evidenced by a history of chronic systemic steroid use? (Topical steroids (except on the study extremity) and steroid inhalants will be allowed in the study.)
Does the subject have Lupus or Crohn's disease?
Does the subject have an oxygen dependency?
Has the subject received hyperbaric oxygen therapy within the previous 90 days?
Has the subject had vascular surgery relating to the wound within 30 days prior to the Screening Visit?
Does the subject have an active Charcot foot deformity of the foot presenting the ulcer?
Has the subject received Dermagraft®, Apligraf, or any other biologically active wound care product, or used Regranex Gel®, KGF, TGFβ or another topical growth factor to the study ulcer within the 30 days prior to the Screening visit?
Does the subject's wound require the use of topical silver, topical antibiotics, enzymatic debridement agents or other topical agents?
Has the subject been enrolled in any investigational study within 30 days of the Screening Visit?
Does the subject have any medical condition that in the opinion of the investigator should exclude him/her from participating in the study?
Has the subject received ultrasonic debridement or electrical stimulation within 7 days of the Screening Visit?
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joseph V Boykin, MD
Organizational Affiliation
HCA Retreat Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Terry Treadwell, MD
City
Montgomery
State/Province
Alabama
ZIP/Postal Code
36111
Country
United States
Facility Name
Alex Reyzelman, DPM
City
Castro Valley
State/Province
California
ZIP/Postal Code
94546
Country
United States
Facility Name
Wyatt Payne, MD
City
Bay Pines
State/Province
Florida
ZIP/Postal Code
33744
Country
United States
Facility Name
Vickie Driver, DPM
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
Facility Name
William Marston, MD
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Facility Name
Joseph Boykin, MD
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23220
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
16008735
Citation
Schultz G, Mozingo D, Romanelli M, Claxton K. Wound healing and TIME; new concepts and scientific applications. Wound Repair Regen. 2005 Jul-Aug;13(4 Suppl):S1-11. doi: 10.1111/j.1067-1927.2005.1304S1.x. No abstract available.
Results Reference
background
PubMed Identifier
15230830
Citation
Keast DH, Bowering CK, Evans AW, Mackean GL, Burrows C, D'Souza L. MEASURE: A proposed assessment framework for developing best practice recommendations for wound assessment. Wound Repair Regen. 2004 May-Jun;12(3 Suppl):S1-17. doi: 10.1111/j.1067-1927.2004.0123S1.x.
Results Reference
background
PubMed Identifier
15147994
Citation
Mustoe T. Understanding chronic wounds: a unifying hypothesis on their pathogenesis and implications for therapy. Am J Surg. 2004 May;187(5A):65S-70S. doi: 10.1016/S0002-9610(03)00306-4.
Results Reference
background
PubMed Identifier
14757419
Citation
Falanga V. The chronic wound: impaired healing and solutions in the context of wound bed preparation. Blood Cells Mol Dis. 2004 Jan-Feb;32(1):88-94. doi: 10.1016/j.bcmd.2003.09.020.
Results Reference
background
PubMed Identifier
17259515
Citation
Xu L, McLennan SV, Lo L, Natfaji A, Bolton T, Liu Y, Twigg SM, Yue DK. Bacterial load predicts healing rate in neuropathic diabetic foot ulcers. Diabetes Care. 2007 Feb;30(2):378-80. doi: 10.2337/dc06-1383. No abstract available.
Results Reference
background
PubMed Identifier
16759300
Citation
Blakytny R, Jude E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med. 2006 Jun;23(6):594-608. doi: 10.1111/j.1464-5491.2006.01773.x.
Results Reference
background
PubMed Identifier
12822725
Citation
Steed DL. Wound-healing trajectories. Surg Clin North Am. 2003 Jun;83(3):547-55, vi-vii. doi: 10.1016/S0039-6109(02)00208-6.
Results Reference
background
PubMed Identifier
10896369
Citation
Robson MC, Hill DP, Woodske ME, Steed DL. Wound healing trajectories as predictors of effectiveness of therapeutic agents. Arch Surg. 2000 Jul;135(7):773-7. doi: 10.1001/archsurg.135.7.773.
Results Reference
background
PubMed Identifier
12766096
Citation
Margolis DJ, Gelfand JM, Hoffstad O, Berlin JA. Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2003 Jun;26(6):1696-700. doi: 10.2337/diacare.26.6.1696.
Results Reference
background
PubMed Identifier
12485449
Citation
Gelfand JM, Hoffstad O, Margolis DJ. Surrogate endpoints for the treatment of venous leg ulcers. J Invest Dermatol. 2002 Dec;119(6):1420-5. doi: 10.1046/j.1523-1747.2002.19629.x.
Results Reference
background
PubMed Identifier
16799391
Citation
Sheehan P, Jones P, Giurini JM, Caselli A, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Plast Reconstr Surg. 2006 Jun;117(7 Suppl):239S-244S. doi: 10.1097/01.prs.0000222891.74489.33.
Results Reference
background
PubMed Identifier
16650209
Citation
Steed DL, Hill DP, Woodske ME, Payne WG, Robson MC. Wound-healing trajectories as outcome measures of venous stasis ulcer treatment. Int Wound J. 2006 Mar;3(1):40-7. doi: 10.1111/j.1742-4801.2006.00178.x.
Results Reference
background
PubMed Identifier
10809855
Citation
Kantor J, Margolis DJ. A multicentre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks. Br J Dermatol. 2000 May;142(5):960-4. doi: 10.1046/j.1365-2133.2000.03478.x.
Results Reference
background
PubMed Identifier
15739652
Citation
Greener B, Hughes AA, Bannister NP, Douglass J. Proteases and pH in chronic wounds. J Wound Care. 2005 Feb;14(2):59-61. doi: 10.12968/jowc.2005.14.2.26739. No abstract available.
Results Reference
background
PubMed Identifier
16885646
Citation
Karim RB, Brito BL, Dutrieux RP, Lassance FP, Hage JJ. MMP-2 assessment as an indicator of wound healing: A feasibility study. Adv Skin Wound Care. 2006 Jul-Aug;19(6):324-7. doi: 10.1097/00129334-200607000-00011.
Results Reference
background
PubMed Identifier
18274183
Citation
Pirayesh A, Dessy LA, Rogge FJ, Hoeksema HJ, Sinove YM, Dall' Antonia A, Jawad MA, Gilbert PM, Rubino C, Scuderi N, Blondeel R, Monstrey S. The efficacy of a polyhydrated ionogen impregnated dressing in the treatment of recalcitrant diabetic foot ulcers: a multi-centre pilot study. Acta Chir Belg. 2007 Nov-Dec;107(6):675-81. doi: 10.1080/00015458.2007.11680145.
Results Reference
background
PubMed Identifier
17387598
Citation
van Rossum M, Vooijs DP, Walboomers XF, Hoekstra MJ, Spauwen PH, Jansen JA. The influence of a PHI-5-loaded silicone membrane, on cutaneous wound healing in vivo. J Mater Sci Mater Med. 2007 Jul;18(7):1449-56. doi: 10.1007/s10856-006-0112-z. Epub 2007 Mar 27.
Results Reference
background
PubMed Identifier
11859942
Citation
Schmidtchen A, Wolff H, Hansson C. Differential proteinase expression by Pseudomonas aeruginosa derived from chronic leg ulcers. Acta Derm Venereol. 2001 Nov-Dec;81(6):406-9. doi: 10.1080/000155501317208336.
Results Reference
background
PubMed Identifier
17477392
Citation
Edwards JV, Howley PS. Human neutrophil elastase and collagenase sequestration with phosphorylated cotton wound dressings. J Biomed Mater Res A. 2007 Nov;83(2):446-54. doi: 10.1002/jbm.a.31171.
Results Reference
background
PubMed Identifier
17479791
Citation
Rushton I. Understanding the role of proteases and pH in wound healing. Nurs Stand. 2007 Apr 18-24;21(32):68, 70, 72 passim. doi: 10.7748/ns2007.04.21.32.68.c4499.
Results Reference
background
PubMed Identifier
18494624
Citation
Gethin GT, Cowman S, Conroy RM. The impact of Manuka honey dressings on the surface pH of chronic wounds. Int Wound J. 2008 Jun;5(2):185-94. doi: 10.1111/j.1742-481X.2007.00424.x.
Results Reference
background
PubMed Identifier
8392530
Citation
Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol. 1993 Jul;101(1):64-8. doi: 10.1111/1523-1747.ep12359590.
Results Reference
background
PubMed Identifier
10998429
Citation
Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair (review). Int J Mol Med. 2000 Oct;6(4):391-407.
Results Reference
background
PubMed Identifier
18387077
Citation
Muller M, Trocme C, Lardy B, Morel F, Halimi S, Benhamou PY. Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP-1 to TIMP-1 is a predictor of wound healing. Diabet Med. 2008 Apr;25(4):419-26. doi: 10.1111/j.1464-5491.2008.02414.x.
Results Reference
background
PubMed Identifier
15978664
Citation
Schonfelder U, Abel M, Wiegand C, Klemm D, Elsner P, Hipler UC. Influence of selected wound dressings on PMN elastase in chronic wound fluid and their antioxidative potential in vitro. Biomaterials. 2005 Nov;26(33):6664-73. doi: 10.1016/j.biomaterials.2005.04.030.
Results Reference
background
PubMed Identifier
12093340
Citation
Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002 Jul;137(7):822-7. doi: 10.1001/archsurg.137.7.822.
Results Reference
background
PubMed Identifier
18494625
Citation
Smeets R, Ulrich D, Unglaub F, Woltje M, Pallua N. Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. Int Wound J. 2008 Jun;5(2):195-203. doi: 10.1111/j.1742-481X.2007.00367.x.
Results Reference
background
PubMed Identifier
16949521
Citation
Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diabetes Complications. 2006 Sep-Oct;20(5):329-35. doi: 10.1016/j.jdiacomp.2005.08.007.
Results Reference
background
PubMed Identifier
11023917
Citation
Fasciglione GF, Marini S, D'Alessio S, Politi V, Coletta M. pH- and temperature-dependence of functional modulation in metalloproteinases. A comparison between neutrophil collagenase and gelatinases A and B. Biophys J. 2000 Oct;79(4):2138-49. doi: 10.1016/S0006-3495(00)76461-7.
Results Reference
background
PubMed Identifier
9927539
Citation
Nwomeh BC, Liang HX, Cohen IK, Yager DR. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J Surg Res. 1999 Feb;81(2):189-95. doi: 10.1006/jsre.1998.5495.
Results Reference
background
Learn more about this trial
A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers
We'll reach out to this number within 24 hrs